Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,
Titel:
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,
Auteur:
Robert, Caroline Gastman, Brian Gogas, Helen Rutkowski, Piotr Long, Georgina V. Chaney, Marya F. Joshi, Harshada Lin, Yu-Lin Snyder, Wendy Chesney, Jason A.